172 related articles for article (PubMed ID: 30305449)
1. Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study.
Bergman J; Burman J; Gilthorpe JD; Zetterberg H; Jiltsova E; Bergenheim T; Svenningsson A
Neurology; 2018 Nov; 91(20):e1893-e1901. PubMed ID: 30305449
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.
Bergman J; Burman J; Bergenheim T; Svenningsson A
J Neurol; 2021 Feb; 268(2):651-657. PubMed ID: 32901316
[TBL] [Abstract][Full Text] [Related]
3. The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
Topping J; Dobson R; Lapin S; Maslyanskiy A; Kropshofer H; Leppert D; Giovannoni G; Evdoshenko E
Mult Scler Relat Disord; 2016 Mar; 6():49-53. PubMed ID: 27063622
[TBL] [Abstract][Full Text] [Related]
4. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.
Bhargava P; Wicken C; Smith MD; Strowd RE; Cortese I; Reich DS; Calabresi PA; Mowry EM
Mult Scler Relat Disord; 2019 May; 30():136-140. PubMed ID: 30771580
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
[TBL] [Abstract][Full Text] [Related]
6. Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.
Svenningsson A; Bergman J; Dring A; Vågberg M; Birgander R; Lindqvist T; Gilthorpe J; Bergenheim T
Neurol Neuroimmunol Neuroinflamm; 2015 Apr; 2(2):e79. PubMed ID: 25745637
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.
Romme Christensen J; Ratzer R; Börnsen L; Lyksborg M; Garde E; Dyrby TB; Siebner HR; Sorensen PS; Sellebjerg F
Neurology; 2014 Apr; 82(17):1499-507. PubMed ID: 24682973
[TBL] [Abstract][Full Text] [Related]
8. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
de Flon P; Gunnarsson M; Laurell K; Söderström L; Birgander R; Lindqvist T; Krauss W; Dring A; Bergman J; Sundström P; Svenningsson A
Neurology; 2016 Jul; 87(2):141-7. PubMed ID: 27316241
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for secondary progressive multiple sclerosis: a case series.
Rommer PS; Patejdl R; Winkelmann A; Benecke R; Zettl UK
CNS Drugs; 2011 Jul; 25(7):607-13. PubMed ID: 21699272
[TBL] [Abstract][Full Text] [Related]
10. Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS.
Bergman J; Svenningsson A; Liv P; Bergenheim T; Burman J
Fluids Barriers CNS; 2020 Jul; 17(1):49. PubMed ID: 32727487
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.
Assouline S; Buccheri V; Delmer A; Gaidano G; Trneny M; Berthillon N; Brewster M; Catalani O; Li S; McIntyre C; Sayyed P; Badoux X
Lancet Haematol; 2016 Mar; 3(3):e128-38. PubMed ID: 26947201
[TBL] [Abstract][Full Text] [Related]
12. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
[TBL] [Abstract][Full Text] [Related]
13. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Panitch H; Miller A; Paty D; Weinshenker B;
Neurology; 2004 Nov; 63(10):1788-95. PubMed ID: 15557491
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland.
Airas L; Nylund M; Mannonen I; Matilainen M; Sucksdorff M; Rissanen E
Mult Scler Relat Disord; 2020 May; 40():101980. PubMed ID: 32066031
[TBL] [Abstract][Full Text] [Related]
15. B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.
Fluge Ø; Risa K; Lunde S; Alme K; Rekeland IG; Sapkota D; Kristoffersen EK; Sørland K; Bruland O; Dahl O; Mella O
PLoS One; 2015; 10(7):e0129898. PubMed ID: 26132314
[TBL] [Abstract][Full Text] [Related]
16. Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
Studer V; Rossi S; Motta C; Buttari F; Centonze D
J Neuroimmunol; 2014 Nov; 276(1-2):229-31. PubMed ID: 25175066
[TBL] [Abstract][Full Text] [Related]
17. [Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia].
Šimkovič M; Vodárek P; Motyčková M; Žák P; Smolej L
Vnitr Lek; 2015; 61(7-8):626-32. PubMed ID: 26375688
[TBL] [Abstract][Full Text] [Related]
18. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.
Harris VK; Vyshkina T; Sadiq SA
Cytotherapy; 2016 Dec; 18(12):1476-1482. PubMed ID: 27727015
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stem cell-derived neural progenitors in progressive MS: Two-year follow-up of a phase I study.
Harris VK; Stark JW; Yang S; Zanker S; Tuddenham J; Sadiq SA
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33277427
[TBL] [Abstract][Full Text] [Related]
20. Predictors of hospitalization due to infection in rituximab-treated MS patients.
Karlowicz JR; Klakegg M; Aarseth JH; Bø L; Myhr KM; Torgauten HM; Torkildsen Ø; Wergeland S
Mult Scler Relat Disord; 2023 Mar; 71():104556. PubMed ID: 36842313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]